Can You Take Weight Loss Injections When Breastfeeding?

Why aren't weight loss injections suitable during breastfeeding?

The short answer is that we don't have enough human data to say they are safe, and that gap matters. Regulatory agencies and the manufacturers of both Mounjaro and Wegovy have taken the precautionary position: breastfeeding should be stopped before either medicine is started. This isn't a bureaucratic formality. GLP-1 and dual GIP/GLP-1 receptor agonists like tirzepatide work partly by slowing gastric emptying and reducing appetite, effects mediated by signalling pathways that are not yet well characterised in the context of lactation.

Animal studies for tirzepatide showed that the medicine was present in milk, but animal data don't translate directly to humans, especially when it comes to neonatal exposure risk. For semaglutide, the picture is similarly incomplete. The NHS medicines page for tirzepatide states clearly that it should not be used while breastfeeding. Given that these are relatively new medicines still under enhanced MHRA monitoring (both carry a Black Triangle designation), the evidence base will grow over time, but it isn't there yet.

It's also worth noting that weight loss itself, if rapid, can have effects on milk composition and supply. This is a separate consideration from the medicine's direct pharmacological effects, but it reinforces why clinicians approach post-partum weight management carefully rather than urgently.

Does it matter whether you're still in the early months or further along?

From a licensing standpoint, the guidance doesn't draw a line at a particular stage of breastfeeding. Whether a baby is three weeks old or nine months old, the recommendation stays the same. A prescriber cannot initiate Mounjaro or Wegovy while you are breastfeeding, regardless of how far along you are or how infrequently you are feeding.

That said, if you're thinking practically about timing, many people find it helpful to talk with their GP or midwife about when they plan to stop breastfeeding, and then to factor in a realistic wash-out period before starting any weight management medicine. The exact interval to allow isn't specified in the product information in the same way it is for conception (where specific guidance exists), so this is genuinely a conversation to have with a clinician who knows your situation, not something to estimate from general reading.

If you'd like to understand more about what the treatment journey looks like once the time is right, the weight loss injection overview on our site covers the full process, and you can always get in touch with our team with questions.

What about trying to conceive, or pregnancy itself?

The same precautionary position applies at every stage around pregnancy. Neither Mounjaro nor Wegovy is recommended during pregnancy or when trying to conceive. The MHRA advises that women of childbearing age use effective contraception while on these medicines.

There is a specific consideration for tirzepatide and oral contraceptives: because tirzepatide slows gastric emptying, absorption of a pill taken orally may be reduced, particularly in the early weeks of treatment and after each dose step up. NHS England's guidance on weight management injections advises adding a non-oral method of contraception for the first four weeks of tirzepatide treatment and for four weeks after any dose increase. There is no equivalent evidence of this interaction for semaglutide, but using reliable contraception throughout treatment with either medicine is sensible practice.

If pregnancy occurs while someone is on treatment, they should stop immediately and speak to a healthcare professional. The same applies if breastfeeding begins while on treatment, stopping is the right course and the prescriber should be informed. You can read more about how long these treatments are used for, which covers pauses and stopping points in more detail.

When might it be appropriate to start treatment, and who decides?

This is probably the question that matters most if you're reading this page while breastfeeding and feeling frustrated that a treatment you've been waiting to try is still out of reach. That frustration is completely understandable. Post-partum weight management is genuinely difficult, and the timeline can feel long.

Once breastfeeding has ended, the next step is a clinical assessment with a prescriber. At nume, at nume, that means a real GPhC-registered Independent Prescriber reading your answers, not an algorithm, and making a decision based on your full health picture. Eligibility for Mounjaro or Wegovy as a private prescription requires a BMI of 30 or above, or a BMI of 27 or above alongside a weight-related health condition; if you want a fuller picture of what using weight loss injections while breastfeeding means for your eligibility and timing, our dedicated page walks through the clinical detail. Other factors including your medical history, current medicines and timing since stopping breastfeeding all come into the assessment.

The latest licensed injections for weight loss in the UK include both tirzepatide and semaglutide, and there is now also a licensed oral option worth knowing about. Our clinical team, led by our clinical pharmacist prescriber, is available to answer questions seven days a week, including on topics such as how weight loss injections and breastfeeding interact from a pharmacological standpoint. When you're ready to explore whether treatment is right for you, a free consultation with our prescribers is the place to start.